SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
National Health Spending In 2006: A Year Of Change For Prescription Drugs
0 references·13 citing·39 second hop
National Health Spending In 2006: A Year Of Change For Prescription Drugs (2008)National Health Spending In 2006: A Year …Medical facility network design: User-choice and system-optimal models (2018)Medical facility network desi…Exploring the impact of operating model choice on the governance of inter-organizational workflow: the U.S. e-prescribing network (2012)Exploring the impact of opera…Changes In US Spending On Mental Health And Substance Abuse Treatment, 1986–2005, And Implications For Policy (2011)Changes In US Spending On Men…Health Spending Growth At A Historic Low In 2008 (2010)Health Spending Growth At A H…Barriers to Achieving Sustainability-Based Decision Making (2010)Barriers to Achieving Sustain…The Obama Administration's Options for Health Care Cost Control: Hope Versus Reality (2009)The Obama Administration's Op…National Health Spending In 2007: Slower Drug Spending Contributes To Lowest Rate Of Overall Growth Since 1998 (2009)National Health Spending In 2…Measuring Quality of Surgical Care: Is It Attainable? (2009)Measuring Quality of Surgical…30 Years of Pharmaceutical Cost-Utility Analyses (2009)30 Years of Pharmaceutical Co…Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point (2008)Prescription Drug Spending Tr…Moral hazard in insurance, value-based cost sharing, and the benefits of blissful ignorance (2008)Moral hazard in insurance, va…Incentives for orphan drug research and development in the United States (2008)Incentives for orphan drug re…Community Care of North Carolina: Improving Care Through Community Health Networks (2008)Community Care of North Carol…Medical insurance: A case study of the tradeoff between risk spreading and appropriate incentives (1970)Free for all?: lessons from the Rand Health Insurance Experiment (1994)Free for All? Lessons from the RAND Health Insurance Experiment (1995)Pauvreté, Egalité, Mortalité: mortality (in)equality in France and the United States (2019)Cost-Effectiveness in Health and Medicine (1996)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)Methods for the Economic Evaluation of Health Care Programmes (2005)A journey of hope: lessons learned from studies on rare diseases and orphan drugs (2006)Economics of New Oncology Drug Development (2007)Market incentives and pharmaceutical innovation (2008)Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases (2013)Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? (2017)Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases (2021)Trends In Medicaid Physician Fees, 2003–2008 (2009)Measuring The Health Of Nations: Updating An Earlier Analysis (2008)An analysis of Liberia's 2007 national health policy: lessons for health systems strengthening and chronic disease care in poor, post-conflict countries (2011)'It's whanaungatanga and all that kind of stuff': Maori cancer patients’ experiences of health services (2013)With big data comes big responsibility (2014)The Social Transformation of American Medicine (1984)High and Rising Health Care Costs. Part 1: Seeking an Explanation (2005)Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)Prescription drug cost sharing: associations with medication and medical utilization and spending and health. (2007)Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers (2007)State Generic Substitution Laws Can Lower Drug Outlays Under Medicaid (2010)Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists (2013)Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Utilization of specialty mental health care among persons with severe mental illness: the roles of demographics, need, insurance, and risk. (2000)Prevalence and Treatment of Mental Disorders (2005)Prevalence and Treatment of Mental Disorders, 1990 to 2003 (2005)Mental health system in Saudi Arabia: an overview (2013)What is needed to eradicate the depression epidemic, and why (2019)On the Front Lines: The Impact of Managerialism on the New York City Addiction Treatment Workforce (2021)Stability in Competition (1929)Conditional logit analysis of qualitative choice behavior (1972)Stability in Competition (1990)Healthcare Facility Location-Allocation Optimization for China’s Developing Cities Utilizing a Multi-Objective Decision Support Approach (2018)Facility location and capacity planning considering policy preference and uncertain demand under the One Belt One Road initiative (2020)Locate vaccination stations considering travel distance, operational cost, and work schedule (2020)Facts, Fallacies, and Politics of Comparative Effectiveness Research: Part I. Basic Considerations (2010)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2008Community Care of North Carolina: Improving Care Through Community Health Networks167 cited
  • 2008Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point142 cited
  • 2008Incentives for orphan drug research and development in the United States138 cited
  • 2009National Health Spending In 2007: Slower Drug Spending Contributes To Lowest Rate Of Overall Growth Since 1998126 cited
  • 2011Changes In US Spending On Mental Health And Substance Abuse Treatment, 1986–2005, And Implications For Policy123 cited
  • 2008Moral hazard in insurance, value-based cost sharing, and the benefits of blissful ignorance88 cited
  • 2009The Obama Administration's Options for Health Care Cost Control: Hope Versus Reality88 cited
  • 2010Health Spending Growth At A Historic Low In 200880 cited
  • 200930 Years of Pharmaceutical Cost-Utility Analyses78 cited
  • 2018Medical facility network design: User-choice and system-optimal models39 cited
  • 2012Exploring the impact of operating model choice on the governance of inter-organizational workflow: the U.S. e-prescribing network26 cited
  • 2009Measuring Quality of Surgical Care: Is It Attainable?24 cited
  • 2010Barriers to Achieving Sustainability-Based Decision Making4 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work